FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: (A
risk consider coverage with another anticoagulant if ELIQUIS is discontinued To report SUSPECTED ADVERSE REACTIONS
pi eliquis
PrELIQUIS (apixaban) Product Monograph
7 oct. 2019 Registered trademark of Bristol-Myers Squibb Company used under ... Hypersensitivity to ELIQUIS (apixaban) or to any ingredients of the ...
ELIQUIS EN PM
ELIQUIS (apixaban) label
To report SUSPECTED ADVERSE REACTIONS contact Bristol-Myers. Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
s lbl
Sign-up Form for the Bristol-Myers Squibb Patient Assistance
ABILIFY is a trademark of Otsuka Pharmaceutical Co. Ltd. ELIQUIS
BristolMyersSquibbPatientAssistanceFoundationFaxForm
Bristol-Myers Squibb – Recall of Eliquis (apixaban)
13 juin 2017 OptumRx® specializes in the delivery clinical management and affordability of prescription medications and consumer health products.
drugrecall eliquis
2012 Annual Report
11 mars 2013 The scientific journey that resulted in Eliquis (apixaban) Bristol-Myers Squibb's new anticoagulation therapy that works by directly ...
Bristol Myers Squibb AR lr
AusPAR Attachment 1: Product Information for Eliquis (Apixaban)
21 juin 2013 Attachment 1: Product information for AusPAR Eliquis Apixaban Bristol-Myers Squibb Australia. Pty Ltd PM-2011-03165-3-3 Date of Finalisation ...
auspar apixaban pi
Eliquis INN-apixaban
The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be Bristol-Myers Squibb/Pfizer EEIG. Plaza 254.
eliquis epar product information en
Presseinformation Bristol-Myers Squibb und Pfizer stellen neue
Bristol-Myers Squibb und Pfizer stellen neue Daten zu. Apixaban (Eliquis®) auf dem ESC-Kongress 2015 vor. • Präsentiert werden 22 Abstracts darunter neue
Pressemitteilung Neue Daten zu Apixaban auf dem ESC Kongres
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
20 juin 2012 Bristol-Myers Squibb and Pfizer. Single technology appraisal (STA). 17 th. August 2012. Page 2. Apixaban – BMS and Pfizer.